Myron Holubiak, general manager of the Plymouth Group IMS subsidiary, is rejoining Roche as president of the U.S. drug business. Holubiak was in marketing, health economics and product management at Roche before going off to start his own consulting firm 13 years ago. Holubiak sold that firm, Emron, to IMS in 1994 and stayed on as a senior IMS manager. Holubiak replaces Steve Sudovar, who left the company in late October. Both Sudovar and Holubiak began their careers within Roche and subsequently formed outside consulting businesses before being recruited back to the company by Roche CEO Patrick Zenner to run the U.S. drug business
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth